Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; no BMI minimum stated; conditions: Heart Failure; Heart Valve Prosthesis
- Interventions
- semaglutide; Dapagliflozin (10mg Tab)
- Conditions
- Heart Failure; Heart Valve Prosthesis
- Phase and size
- Phase 2 · 160 participants
- Dates
- Start 2025-06-02
Primary completion 2026-04-29 - Sponsor
- Kafrelsheikh University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change from Baseline in Left Ventricular Global Longitudinal Strain (LV-GLS) assessed by echocardiographyBaseline and 12 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Age is at least 18 years at the time of screening. * Confirmed diagnosis of heart failure. * Documented history of surgical prosthetic heart valve replacement. * Patient is currently on a stable baseline regimen of dapagliflozin (10 mg once daily). * Patient is willing and able to provide written informed consent prior to any study-related procedures. Exclusion Criteria: * Known hypersensitivity or allergy to semaglutide, dapagliflozin, or any of their excipients. * Type 1 diabetes mellitus. * Severe renal impairment (e.g., eGFR \< 25 or 30 mL/min/1.73m², depending on your exact protocol threshold) or currently requiring dialysis. * Active pregnancy, breastfeeding, or intent to become pregnant during the 12-week study period. * Participation in another conflicting interventional clinical trial within the past 30 days.
03Change log
Registry changes
No changes recorded since the trial was added.